A. Pieters

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

C. Bailey, J. Gross, J. List, 2010, The Lancet.

CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC).

R. Govindan, P. Postmus, S. Peters, 2016 .

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

M. Hellmann, V. Moreno, J. Eder, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Michael Thomas, Yi-long Wu, E. Felip, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.

D. Schadendorf, P. Ascierto, J. Weber, 2021, European journal of cancer.

CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).

S. Gettinger, S. Peters, D. Spigel, 2016 .